Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ)
Taiyuan, CN
Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. operates extensively within the country, focusing on biochemical engineering, the production of pharmaceutical industry equipment, and medical materials. The company's diverse product portfolio includes a range of vital human blood-derived therapies such as serum albumin, various forms of human immunoglobulin (including specific preparations for rabies, hepatitis B, tetanus, and intravenous human immunoglobulin (PH4)). They also manufacture topical remedies like tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, and dieshangling plasters, alongside general medical gauzes. Beyond current offerings, Pacific Shuanglin is actively engaged in developing advanced biopharmaceutical products, including porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. Furthermore, the company expands its interests to encompass investment, consultation, and technology promotion for pharmaceutical and biotechnology projects. Its broader ventures include real estate development, electronic product information services, and the provision of electricity. The entity adopted its current name, Pacific Shuanglin Bio-pharmacy Co., Ltd., in April 2021, having previously been known as Southern Shuanglin Bio-pharmacy Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.22% | +12.27% | +6.00% | -8.58% | -14.06% | -5.77% | -24.16% | -22.99% | -52.24% | +43.17% | +2,135.66% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-0.8% Q1'26: -8.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-56.9% Q1'26: -83.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-16.4% Q1'26: -60.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.7% ★ Q1'26: +9.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.6% Q1'26: +1.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+30.4% Q1'26: +54.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.12× ★ Q1'26: 5.24× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
561.21M
est: 578.81M (-3.0%)
|
685.38M
est: 752.46M (-8.9%)
|
859.84M
est: 856.00M (+0.4%)
|
915.66M
est: 971.00M (-5.7%)
|
1.05B
est: 1.12B (-6.2%)
|
1.97B
est: 1.86B (+6.2%)
|
2.41B
est: 2.39B (+0.6%)
|
2.33B
est: 2.36B (-1.5%)
|
2.65B
est: 2.96B (-10.4%)
|
2.63B
est: 2.57B (+2.4%)
|
2.98B
2.98B – 2.98B
+15.7% YoY
|
3.39B
3.39B – 3.39B
+13.7% YoY
|
| EBITDA |
127.79M
est: 173.87M (-26.5%)
|
158.46M
est: 226.04M (-29.9%)
|
166.52M
est: 257.14M (-35.2%)
|
237.17M
est: 291.68M (-18.7%)
|
273.96M
est: 336.38M (-18.6%)
|
538.01M
est: 557.54M (-3.5%)
|
704.63M
est: 717.95M (-1.9%)
|
770.71M
est: 710.11M (+8.5%)
|
913.93M
est: 760.67M (+20.1%)
|
660.62M
est: 660.69M (0.0%)
|
764.73M
764.73M – 764.73M
+15.7% YoY
|
869.79M
869.79M – 869.79M
+13.7% YoY
|
| EBIT |
78.47M
est: 144.58M (-45.7%)
|
109.97M
est: 187.96M (-41.5%)
|
117.49M
est: 213.82M (-45.1%)
|
190.87M
est: 242.54M (-21.3%)
|
226.59M
est: 279.71M (-19.0%)
|
430.20M
est: 463.61M (-7.2%)
|
587.01M
est: 596.99M (-1.7%)
|
633.70M
est: 590.48M (+7.3%)
|
793.13M
est: 608.68M (+30.3%)
|
518.49M
est: 528.67M (-1.9%)
|
611.92M
611.92M – 611.92M
+15.7% YoY
|
695.99M
695.99M – 695.99M
+13.7% YoY
|
| Net Income |
50.09M
est: 143.75M (-65.2%)
|
21.60M
est: 65.77M (-67.2%)
|
79.98M
est: 132.16M (-39.5%)
|
160.45M
est: 215.62M (-25.6%)
|
185.97M
est: 179.31M (+3.7%)
|
391.06M
est: 385.59M (+1.4%)
|
587.13M
est: 432.80M (+35.7%)
|
612.11M
est: 472.15M (+29.6%)
|
745.32M
est: 776.97M (-4.1%)
|
419.27M
est: 667.01M (-37.1%)
|
790.89M
790.89M – 790.89M
+18.6% YoY
|
905.23M
905.23M – 905.23M
+14.5% YoY
|
| SGA |
220.26M
est: 124.47M (+77.0%)
|
238.13M
est: 161.81M (+47.2%)
|
303.00M
est: 184.07M (+64.6%)
|
256.55M
est: 208.80M (+22.9%)
|
276.16M
est: 240.80M (+14.7%)
|
419.00M
est: 399.11M (+5.0%)
|
565.05M
est: 513.94M (+9.9%)
|
465.81M
est: 508.33M (-8.4%)
|
437.26M
est: 545.71M (-19.9%)
|
287.63M
est: 473.98M (-39.3%)
|
548.62M
548.62M – 548.62M
+15.7% YoY
|
623.99M
623.99M – 623.99M
+13.7% YoY
|
| EPS |
0.09
est: 0.20 (-52.2%)
|
0.04
est: 0.09 (-54.9%)
|
0.15
est: 0.18 (-17.1%)
|
0.33
est: 0.30 (+11.8%)
|
0.38
est: 0.25 (+54.9%)
|
0.55
est: 0.53 (+4.2%)
|
0.80
est: 0.59 (+35.1%)
|
0.84
est: 0.65 (+30.0%)
|
1.02
est: 0.82 (+25.1%)
|
0.44
est: 0.70 (-37.1%)
|
0.83
0.83 – 0.83
+18.6% YoY
|
0.95
0.95 – 0.95
+14.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 54.5K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 226.1K | 0.39% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.6K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.9K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.62M | 0.06% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 82.7K | 0.28% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 60.8K | 0.29% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 25.6K | 0.10% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.76M | 0.05% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.6K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lan Ye | Deputy GM & Non-Independent Director | — | female |
| Lei Yan | Deputy GM & Director | — | male |
| Qunge Zhang | Deputy General Manager | — | male |
| Wenbin Si | Deputy GM & Non-Independent Director | — | male |
| Xiankui Rong | General Manager | — | male |
| Xiaoying Huang | Deputy GM & Non-Independent Director | — | female |
| Yehong Wang | CFO, Head of Accounting Department & Accounting Supervisor | — | female |
| Yulin Zhao | Board Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000403.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
